Two molecules that affected the cell cycle only of acute myeloid leukemia (AML) cells could be used as a clinical strategy against this pathology. Scientists at Memorial Sloan Kettering Cancer Center and Harvard University have discovered that DEG-35 and DEG-77 arrested the cell cycle and promoted cell differentiation and apoptosis in these cells. Read More
IOA-244 is a selective phosphoinositide 3-kinase delta (PIK3δ) inhibitor that is being tested in the clinic for lymphoma and solid tumors. Researchers from Ionctura SA and their collaborators tested IOA-244’s antiproliferative activity in MTT assays at 72 h. Read More
Oryzon Genomics SA has nominated ORY-4001, a selective histone deacetylase 6 (HDAC6) inhibitor, as a clinical development candidate for the treatment of certain neurological diseases, including Charcot-Marie-Tooth (CMT), amyotrophic lateral sclerosis (ALS) and others. Read More
Exevir Bio BV has announced research detailing a novel, highly potent, anti-S2 camelid single-domain antibody, discovered at the VIB-Ugent Center for Medical Biotechnology, and developed as a candidate drug molecule by Exevir as XVR-013. Read More
CD73 is known to induce immune evasion in solid tumors by release of immune-suppressive adenosine in the tumor microenvironment. Researchers from Cidara Therapeutics Inc. have presented preclinical data on the CD73 inhibitor drug FC-conjugate CBO-212 for the potential treatment of solid tumors. Read More
Olatec Therapeutics LLC has been awarded a research grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to evaluate its lead molecule, dapansutrile (OLT-1177), in preclinical Parkinson’s disease progression models. Read More
A recent Moya Bio Ltd. patent describes fused azole and furan-based nucleoside analogues acting as ubiquitin-like modifier-activating enzyme 1 (UBA1; UBE1) inhibitors and thus reported to be potentially useful for the treatment of inflammation, cancer, parasitic infections and autoimmune diseases. Read More
Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations presented data from a study that aimed to investigate the immunomodulatory functions of lysine-specific demethylase 1 (LSD1) in regulating MHC-I antigen presentation pathway (APP) and resistance to immunotherapy in patients with small-cell lung cancer (SCLC). Read More
It has been previously demonstrated that necrosis is associated with metastatic dissemination of cancer cells; however, how necrosis promotes tumor dissemination is not understood. In a recent study, researchers from Fred Hutchinson Cancer Center and University of Washington aimed to investigate the correlation between tumor dissemination and the formation of large contiguous zones of necrosis within the tumor core. Read More
Tetra Bio-Pharma Inc. has received clearance from Health Canada to proceed with a first-in-human trial in Canada using oral ARDS-003 (onternabez) to treat various immunomodulatory conditions. Oral ARDS-003 is positioned to modulate acute systemic inflammation and prevent sepsis, acute respiratory distress syndrome (ARDS) and organ damage. Read More
Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have developed urea compounds containing 2-heteroaromatic ring substitution that act as cyclin-dependent kinase 9 (CDK9) inhibitors. Read More
Researchers from Tonix Pharmaceuticals have presented preclinical data for mTNX-1700 (mTTF2-MSA), a novel recombinant fusion protein with an extended half-life, in anti-PD-1 treated colorectal cancer (CRC) models. Read More
Protein phosphatase 2A (PP2A) is a heterotrimer affecting approximately 60% of all serine/threonine phosphorylations. PP2A functions as a tumor suppressor when it is a trimer (PP2A-A-PP2Ac-B56) containing the B56 subunit. The B56 subunit is known to interact with up to 100 different proteins, but exactly how the PP2Aa/c-B56 complex is disrupted to initiate cancer has been poorly understood until now. Read More
Mindset Pharma Inc. has patented indole derivatives acting as 5-HT2A receptor agonists and reported to be useful for the treatment of neurological disorders and psychosis. Read More
Poikiloderma (a skin condition involving hypopigmentation, hyperpigmentation, spider veins and atrophy) with neutropenia (PN) is a unique clinical presentation that can be caused by mutations in the U6 snRNA biogenesis phosphodiesterase 1 gene (USB1). Curiously enough, the USB1 protein is required for U6 snRNA synthesis in yeast and zebrafish, but not humans. Read More
